Rejoyn – An App for MDD Treatment

Rejoyn, a smartphone app, became the first digital therapeutic to get the nod from the United States Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD) in adults aged 22 and older who are receiving antidepressant medication, announced by Otsuka and Click Therapeutics, the developers of the app.

Rejoyn offers a unique treatment for depression symptoms because it targets neural networks that are impaired by depression and uses the brain's natural neuroplasticity to change those connections over time, thereby reducing symptoms.

It is a six-week program that combines brief therapeutic teachings with clinically validated cognitive-emotional activities for the brain to help improve cognitive control of emotion. The main feature of the app is a unique training exercise where users see a series of faces representing various emotions and then have to remember the order in which they occur. The activities are designed to improve working memory deficiencies for emotional content, which is related to major depressive disorder (MDD). In addition, the app provides customized messages and reminders and three to four-minute animated lectures on cognitive behavioral therapy.

“Only a third of patients diagnosed with depression and who receive antidepressants as their first-line treatment, are successful. These patients need new options that capitalize on proven-effective treatment strategies,” said David Benshoof Klein, Co-founder and chief executive officer at Click Therapeutics.

Rejoyn's approval marks a major change in how doctors can treat serious depression symptoms. For individuals searching for new therapeutic alternatives, it brings hope, especially if the option is readily available through the gadget in your palm.

Website: https://www.marketsandata.com